Tracer library / [68Ga]NOTA-ABDC2

[68Ga]NOTA-ABDC2

Also written as [Ga-68]Ga-NOTA-ABDC2

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: Nanobody-albumin binding domain fusion protein (NOTA-conjugated CD47-targeting nanobody)
Target / mechanism: CD47-targeting agent PMID 36939440
Clinical application: CD47-expressing solid tumors, including gastric cancer patient-derived xenograft models PMID 36939440
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	12.85% ± 0.45 n = 2 not corrected	>99%	NOTA-ABDC2	36939440 2023 Research (Wash D C) The detailed methods for chelator conjugation, 68Ga/89Zr/177Lu-labeling, and quality control of the tracers are provided in the supplemental file. - The nondecay corrected radiochemical yield of [68Ga]Ga-NOTA-C2, [68Ga]Ga-NOTA-ABDC2, and [89Zr]Zr-DFO-ABDC2 were 25.15% ± 10.21 (n = 4), 12.85% ± 0.45 (n = 2), and 99% (n = 1), respectively.

Need this precursor?We can point you to suppliers for [68Ga]NOTA-ABDC2, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36939440. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 36939440. Stage set/updated at stage 39 from PMID 36939440: 'we evaluated the pharmacokinetics and theranostic efficacies of the agents in cell- and patient-derived models'.